Cognitive Behavioral Stress Management for HIV+ Drug Abusers
NCT ID: NCT00722644
Last Updated: 2017-01-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
450 participants
INTERVENTIONAL
1999-09-30
2007-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Behavioral Therapy Development for Methamphetamine Abusers
NCT00249678
Behavioral Depression Treatment for African American HIV-infected Substance Users
NCT01351454
Chronic Hepatitis Intervention Project for Drug Users
NCT00596843
Intervention to Reduce Injection Drug Use
NCT00786630
HIV and HCV Intervention In Drug Treatment Settings - 1
NCT00102349
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cognitive Behavioral Stress Management
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. fluency in spoken English which is required to complete assessments and to participate in the intervention groups;
3. acknowledgement of HIV seropositivity and willingness to be tested to confirm this serostatus;
4. currently not cognitively impaired since cognitive impairment may compromise the ability to comprehend and participate in the assessment and intervention;
5. currently not showing symptoms of a major psychiatric disorder/ including psychosis, or a high risk for suicidality since these conditions might compromise ability to comprehend and participate in the assessment and intervention; and
6. classification as a "Recovering Drug Abusers" (RDAs; 30 days free of substances, 1-36 months recovery from alcohol and other drugs).
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert M. Malow, PhD
Role: PRINCIPAL_INVESTIGATOR
Florida International University
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DA13802
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.